BIOCRYST PHARMACEUTICALS INC (BCRX) — SEC Financial Statements & Analysis

BIOCRYST PHARMACEUTICALS INC (BCRX) is a biological products, (no diagnostic substances) company, incorporated in DE. BIOCRYST PHARMACEUTICALS INC trades on Nasdaq as: BCRX. BIOCRYST PHARMACEUTICALS INC (BCRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, BIOCRYST PHARMACEUTICALS INC carries a market cap of $2.54B, a P/E ratio of -6.62x, a P/B ratio of -5.60x, a P/S ratio of 2.71x, an enterprise value of $2.78B, and an EV/EBITDA multiple of -8.94x. On profitability, it posts a gross margin of 97.78%, an operating margin of -33.29%, a net margin of -40.90%, a Return on Equity (ROE) of 87.84%, and a Return on Assets (ROA) of -75.79%. Per share, it reports EPS of $-1.51, diluted EPS of $-1.45, free cash flow per share of $1.47, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 68.72% year-over-year, net income growth of 977.18% year-over-year, and EPS growth of 786.87% year-over-year. On the balance sheet, it maintains a current ratio of 2.32x, a quick ratio of 2.22x, working capital of $275.84M, a debt-to-equity ratio of -2.23x, a debt ratio of 1.81, an interest coverage ratio of -4.16x, free cash flow of $373.38M (TTM), and net debt of $240.11M. Figures sourced from SEC EDGAR.

Market Cap

$2.54B

P/E TTM

-6.62x

EPS TTM

$-1.51

P/B TTM

-5.60x

ROE TTM

87.84%

ROA TTM

-75.79%

Debt To Equity

-2.23x

Free Cash Flow TTM

$373.38M

Net Revenue TTM Growth 1Y

68.72%

Data as of 2026-06-30 · Source: SEC EDGAR